StockNews.AI
XENE
StockNews.AI
180 days

Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025

1. Xenon will report Q4 2024 results on February 27 after market close. 2. A live webcast and dial-in details are provided for investor participation. 3. Announcement highlights advanced clinical progress including Azetukalner developments.

Earnings
+0.89%Current Return
VS
-1.72%S&P 500
$39.3802/20 04:10 PM EDTEvent Start
$39.7302/21 10:27 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

Earnings announcements typically drive short-term volatility without long-term shifts. Historical Q4 results often resulted in modest price movements.

How important is it?

Earnings reports are fundamental events impacting investor sentiment, though changes are often short-lived unless results surprise.

Why Short Term?

Earnings events generally affect stock prices immediately post-announcement. Past earnings reports have led to transient price adjustments only.

Related Companies

XENE
February 20, 2025 16:01 ET  | Source: Xenon Pharmaceuticals Inc. VANCOUVER, British Columbia and BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its fourth quarter 2024 financial results after the close of U.S. financial markets on Thursday, February 27, 2025. Conference Call/Webcast Information: Date:Thursday, February 27, 2025  Time:4:30 pm Eastern Time (1:30 pm Pacific Time)  Webcast:Pre-register here  Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers  Conference ID:8120798   A live webcast of the company presentation will be available on the “Investors” section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com. “Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner. Contacts: For Investors:Chad FugereVice President, Investor Relations(857) 675-7275investors@xenon-pharma.com For Media:Colleen AlabisoSenior Vice President, Corporate Affairs(617) 671-9238media@xenon-pharma.com

Related News